CEO Benjamin Zeskind was paid $1,660,612 in fiscal year 2025, ↓ down 14.6% from fiscal year 2024 (SEC filing 0001790340-26-000048 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,660,612 ↓ Benjamin Zeskind total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
IMRX's next annual pay disclosure, estimated April 19, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Benjamin Zeskind | $641,493 | $423,385 | $0 | $579,504 | $0 | $0 | $16,230 | $1,660,612 |
| President and Chief Executive Officer | ||||||||
| Brett Hall | 733,468 | 264,048 | 0 | 289,752 | 0 | 0 | 2,236 | 1,289,504 |
| Chief Scientific Officer | ||||||||
| Michael Bookman | 502,089 | 241,003 | 0 | 132,803 | 0 | 0 | 14,468 | 890,362 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Benjamin Zeskind | $1,660,612 | $1,945,092 | $1,918,201 | ↓ −284,480 |
| Brett Hall | 1,289,504 | 1,425,506 | 1,399,319 | ↓ −136,002 |
| Michael Bookman | 890,362 | 1,088,351 | — | ↓ −197,989 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Immuneering's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper IMRX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses IMRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IMRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Benjamin Zeskind | CEO | $1,660,612 |
| Brett Hall | Chief Scientific Officer | $1,289,504 |
| Michael Bookman | General Counsel | $890,362 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Ann E. Berman | Former director (through FY2025) | $55,523 |
| Diana F. Hausman, M.D | Independent Director | $101,521 |
| Laurie B. Keating | Independent Director | $106,811 |
| Peter Feinberg | Independent Director | $103,379 |
| Robert J. Carpenter | Independent Director | $93,521 |
| Thomas J. Schall, Ph.D | Chair of the Board | $104,893 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Benjamin Zeskind | Option | 95,400 | 4.25 | — |
| Michael Bookman | Option | 48,438 | 3.01 | — |
| Benjamin Zeskind | Option | 950 | 10.63 | — |
| Benjamin Zeskind | Option | 3,261 | 9.66 | — |
| Benjamin Zeskind | Option | 5,893 | 4.68 | — |
| Benjamin Zeskind | Option | 8,549 | 6.7 | — |
| Benjamin Zeskind | Option | 127,233 | 6.09 | — |
| Benjamin Zeskind | Option | 370,000 | 1.91 | — |
| Brett Hall | Option | 68,178 | 6.09 | — |
| Brett Hall | Option | 1,732 | 9.66 | — |
| Brett Hall | Option | 50,646 | 4.25 | — |
| Brett Hall | Option | 185,000 | 1.91 | — |
| Michael Bookman | Option | 986 | 3.01 | — |
| Michael Bookman | Option | 38,730 | 3.01 | — |
| Michael Bookman | Option | 84,792 | 1.91 | — |
Our executive compensation program is designed to align compensation with business objectives and the creation of stockholder value, while also enabling us to attract, motivate and retain individuals who contribute to our long-term success.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, an Aon Company |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Laurie B. KeatingIndependent · Audit Committee (Chair) · Compensation Committee | $18,356 | $0 | $88,455 | — | $0 | $106,811 |
| Thomas J. Schall, Ph.DIndependent · Board Chair · Audit · Compensation | 56,372 | 0 | 48,521 | — | 0 | 104,893 |
| Peter FeinbergIndependent · Audit Committee · Nominating and Corporate Governance Committee · Compensation Committee (Chair) | 14,924 | 0 | 88,455 | — | 0 | 103,379 |
| Diana F. Hausman, M.DIndependent · Nominating and Corporate Governance · Compensation | 53,000 | 0 | 48,521 | — | 0 | 101,521 |
| Robert J. CarpenterIndependent · Compensation Committee | 45,000 | 0 | 48,521 | — | 0 | 93,521 |
| Ann E. BermanIndependent · Departed during FY | 12,495 | 0 | 43,028 | — | 0 | 55,523 |
| Benjamin J. Zeskind, Ph.DEmployee director · Compensation | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $200,147 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $200,147 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Immuneering | 2025 | Benjamin Zeskind | $641,493 | $0 | $579,504 | $0 | $1,660,612 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Benjamin Zeskind | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Summary Compensation Table” · page 22. As printed: 1,660,612. Filing ↗machine: span 279343–279352 |
| 2 | Section 01, Brett Hall | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Summary Compensation Table” · page 22. As printed: 1,289,504. Filing ↗machine: span 285490–285499 |
| 3 | Section 01, Michael Bookman | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Summary Compensation Table” · page 22. As printed: 890,362. Filing ↗machine: span 291630–291637 |
| 4 | Section 08, Laurie B. Keating | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Director Compensation”. As printed: 106,811. Filing ↗machine: span 404213–404444 |
| 5 | Section 08, Thomas J. Schall, Ph.D | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Director Compensation”. As printed: 104,893. Filing ↗machine: span 405681–405912 |
| 6 | Section 08, Peter Feinberg | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Director Compensation”. As printed: 103,379. Filing ↗machine: span 401108–401339 |
| 7 | Section 08, Diana F. Hausman, M.D | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Director Compensation”. As printed: 101,521. Filing ↗machine: span 402575–402806 |
| 8 | Section 08, Robert J. Carpenter | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Director Compensation”. As printed: 93,521. Filing ↗machine: span 399474–399704 |
| 9 | Section 08, Ann E. Berman | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Director Compensation”. As printed: 55,523. Filing ↗machine: span 397996–398252 |
| 10 | Section 08, Benjamin J. Zeskind, Ph.D | DEF 14A | 2026-04-20 | 0001790340-26-000048 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 06, 2026 vote | Form 8-K | 2026-04-20 | 0001790340-26-000048 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | — | Cash 200,147 + equity 0 + all other 0 = 200,147, summed across the director compensation table rows.machine: formula: Σ = 200,147 |
| 14 | Immuneering (subject), Section 10b CEO total | DEF 14A | 2026-04-20 | 0001790340-26-000048 | CEO total compensation as printed in Immuneering's own proxy. As printed: 1,660,612. Filing ↗machine: span 279343–279352 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.